Wednesday, March 13, 2013

Sosei announces initiation of Phase III study for SO-1105 for the treatment of oropharyngeal candidiasis

Sosei Co., Ltd., has initiated a Phase III trial for SO-1105 for thetreatment of oropharyngeal candidiasis.
The study is an open-label, randomised, multiple centres, parallel-group design (with open  active comparator miconazole gel), and will assess efficacy and safety of SO-1105.
SO-1105 is an antifungal agent, administered as a muco-adhesive buccal tablet for the  treatment of oropharyngeal candidias is in immunocompromised patients. SO-1105 has the potential to become the first long-acting, sustained-release treatment in tablet form for oropharyngeal candidias is in Japan that could enhance patients’compliance and quality of life.
SO-1105 was originally developed by a French pharmaceutical company, BioAlliance Pharma,  which received its first marketing authorization for SO-1105 in France in October 2006. SO-1105  has since been registered in 24 European countries, in South Korea, and in the United States, under the trade names Loramyc® /Oravig
 






Enter your email address:


Delivered by FeedBurner